Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 2013. The report serves as a notification of transactions involving Directors and Persons Discharging Managerial Responsibility regarding the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of insider share transactions rather than a financial performance report.
Material Changes
The filing details the acquisition of Ordinary Shares by several executives on June 11, 2013, at a price of 1,658.92 pence per share through the Company's ShareReward Plan. Transactions included both personal contributions and matching company contributions:
- Sir Andrew Witty: Acquired 7 shares (personal) and 7 shares (company match).
- Mr S Dingemans: Acquired 7 shares (personal) and 7 shares (company match).
- Mr S M Bicknell: Acquired 7 shares (personal) and 7 shares (company match).
- Mr R G Connor: Acquired 7 shares (personal) and 7 shares (company match).
- Mr D S Redfern: Acquired 7 shares (personal) and 7 shares (company match).
- Ms C Thomas: Acquired 7 shares (personal) and 7 shares (company match).
- Mr P C Thomson: Acquired 6 shares (personal) and 6 shares (company match).
- Dr P J T Vallance: Acquired 8 shares (personal) and 8 shares (company match).
- Ms E Walmsley: Acquired 7 shares (personal) and 7 shares (company match).
- Mrs V A Whyte: Acquired 7 shares (personal) and 7 shares (company match).
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document strictly adheres to Disclosure and Transparency Rule 3.1.4R(1)(a) regarding director share interests.
Investor Verification Points
- Verify the share price of 1,658.92 pence per Ordinary Share on June 11, 2013.
- Confirm the total number of shares acquired by each listed executive under the ShareReward Plan.
- Review the company's broader financial reports (e.g., Form 20-F) for performance metrics not included in this transaction notification.